BCAT

BCAT

BCAT2 catalyzes the first step in the metabolism of BCAAs (leucine, isoleucine and valine) by converting then to their a-keto acids. Downstream metabolites of this pathway have been reported to play a role in Type 2 diabetes, and mutations in downstream enzymes lead to organic acidemias. Inhibition of the BCAA metabolic pathway is anticipated to have potential therapeutic value in treating these disorders. Ligand has identified novel BCAT2 selective inhibitors which are active in cellular assays and demonstrate good oral bioavailability in murine models of metabolic disease.